A Phase II Study Evaluating Combined Zevalin(Ibritumomab Tiuxetan)and Velcade(Bortezomib)in Relapsed/Refractory Mantle Cell Lymphoma.
Phase of Trial: Phase II
Latest Information Update: 16 Jun 2015
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Bortezomib; Rituximab
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- 09 Feb 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
- 12 May 2014 Trial status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 06 Mar 2012 Actual initiation date (Feb 2012) added as reported by ClinicalTrials.gov.